Myovant Sciences Ltd. Increase (Decrease) in Deferred Revenue
Myovant Sciences Ltd. reported Increase (Decrease) in Deferred Revenue of -$9.03 million for the 9-month period ending 2022-12-31, per its 10-Q filed 2023-01-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2023-01-26
- Myovant Sciences Ltd. increase (decrease) in deferred revenue for the quarter ending 2022-12-31 was -$29.31M.
- Myovant Sciences Ltd. increase (decrease) in deferred revenue for the quarter ending 2022-09-30 was $45.42M.
- Myovant Sciences Ltd. increase (decrease) in deferred revenue for the quarter ending 2022-06-30 was -$25.14M, a 135.67% decline year-over-year.
- Myovant Sciences Ltd. increase (decrease) in deferred revenue for the quarter ending 2022-03-31 was -$25.14M.
- Myovant Sciences Ltd. increase (decrease) in deferred revenue for fiscal 2022 was -$21.66M, a 104.73% decline from fiscal 2021.
- Myovant Sciences Ltd. increase (decrease) in deferred revenue for fiscal 2021 was $457.93M, a 1044.83% increase from fiscal 2020.
- Myovant Sciences Ltd. increase (decrease) in deferred revenue for fiscal 2020 was $40.00M.
- Myovant Sciences Ltd. increase (decrease) in deferred revenue for fiscal 2019 was $0.00.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$29.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-01-26 | $16.12M derived: sum of 2 quarters · filed 2023-01-26 | -$9.03M 10-Q · filed 2023-01-26 | -$34.17M derived: sum of 4 quarters · filed 2023-01-26 |
| 2022-09-30 | $45.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-10-26 | $20.28M 10-Q · filed 2022-10-26 | -$4.86M derived: sum of 3 quarters · filed 2022-10-26 | -$30.03M derived: sum of 4 quarters · filed 2023-01-26 |
| 2022-06-30 | -$25.14M 10-Q · filed 2022-07-27 | -$50.28M derived: sum of 2 quarters · filed 2022-07-27 | -$75.46M derived: sum of 3 quarters · filed 2023-01-26 | -$117.30M derived: sum of 4 quarters · filed 2023-01-26 |
| 2022-03-31 | -$25.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-11 | -$50.31M derived: sum of 2 quarters · filed 2023-01-26 | -$92.15M derived: sum of 3 quarters · filed 2023-01-26 | -$21.66M 10-K · filed 2022-05-11 |
| 2021-12-31 | -$25.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-01-26 | -$67.01M derived: sum of 2 quarters · filed 2023-01-26 | $3.48M 10-Q · filed 2023-01-26 | -$17.50M derived: sum of 4 quarters · filed 2023-01-26 |
| 2021-09-30 | -$41.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-10-26 | $28.65M 10-Q · filed 2022-10-26 | $7.68M derived: sum of 3 quarters · filed 2022-10-26 | $509.92M derived: sum of 4 quarters · filed 2022-10-26 |
| 2021-06-30 | $70.49M 10-Q · filed 2022-07-27 | $49.52M derived: sum of 2 quarters · filed 2022-07-27 | $551.76M derived: sum of 3 quarters · filed 2022-07-27 | $551.76M derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-03-31 | -$20.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-11 | $481.27M derived: sum of 2 quarters · filed 2022-05-11 | $481.27M derived: sum of 3 quarters · filed 2022-05-11 | $457.93M 10-K · filed 2022-05-11 |
| 2020-12-31 | $502.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-01-26 | $502.24M derived: sum of 2 quarters · filed 2022-01-26 | $478.91M 10-Q · filed 2022-01-26 | $518.91M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-10-26 | -$23.33M 10-Q · filed 2021-10-26 | $16.67M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-06-30 | -$23.33M 10-Q · filed 2021-07-28 | $16.67M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-03-31 | $40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-11 | $40.00M 10-K · filed 2022-05-11 | ||
| 2019-12-31 | $0.00 10-Q · filed 2021-02-11 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-11 | |||
| 2019-03-31 | $0.00 10-K · filed 2021-05-11 |